Koo J, Lam S K, Ong G B
Ann Surg. 1982 Apr;195(4):406-12. doi: 10.1097/00000658-198204000-00005.
The efficacy of cimetidine vs. surgery in the treatment of recurrent ulcers after definitive surgery for chronic duodenal ulcer was evaluated in two comparable groups (23 each) of patients. Cimetidine 1 g daily healed 79% and 91.6% of recurrent ulcers, as assessed endoscopically, after 6 and 12 weeks respectively. At the end of one year, maintenance treatment with cimetidine (400 mg nocte) prevented relapse in 89.5% of the healed ulcers, while surgery was successful in 94.4% (p greater than 0.1). The cimetidine group experienced significantly (p less than 0.05) less side effects than the surgical group, with respectively 10% and 50% of patients having Visick grade II and above. After one year of maintenance treatment, cimetidine was withdrawn, and ulcer recurred in 71.4% within six months. The relapse rates between the two groups were significantly different by life-table analysis (p less than 0.01). We conclude that cimetidine was as effective as surgery in preventing relapse of postsurgical recurrent ulcers and had fewer side effects, but indefinitely prolonged therapy appeared necessary.
在两组(每组各23例)具有可比性的患者中,评估了西咪替丁与手术治疗慢性十二指肠溃疡确定性手术后复发性溃疡的疗效。每日1克西咪替丁治疗,分别在6周和12周后,经内镜评估,复发性溃疡愈合率分别为79%和91.6%。在一年结束时,用西咪替丁(每晚400毫克)维持治疗可防止89.5%已愈合溃疡复发,而手术成功率为94.4%(p大于0.1)。西咪替丁组的副作用明显(p小于0.05)少于手术组,分别有10%和50%的患者出现Visick II级及以上情况。维持治疗一年后,停用西咪替丁,71.4%的患者在六个月内溃疡复发。通过寿命表分析,两组间的复发率有显著差异(p小于0.01)。我们得出结论,西咪替丁在预防手术后复发性溃疡复发方面与手术效果相当,且副作用较少,但似乎需要无限期延长治疗。